IOVANCE BIOTHERAPEUTICS, INC. (IOVA) Quick Ratio
- Quick ratio · latest quarter: Value 3.74×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 3.74× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $399.79M ÷ $106.85M ≈ 3.74× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 399.79M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 106.85M USD | Liabilities, Current |
| Cash and equivalents | 110.77M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 186.91M USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 102.12M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 55.59M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $399.79M | $106.85M | $110.77M | $186.91M | $102.12M | $55.59M | 3.74× |
| 2026-03-31 | $395.20M | $129.42M | $196.51M | $116.94M | $81.76M | $58.38M | 3.05× |
| 2025-12-31 | $379.43M | $138.36M | $163.08M | $133.90M | $82.45M | $51.68M | 2.74× |
| 2025-09-30 | $367.56M | $125.78M | $158.13M | $142.67M | $66.76M | $51.71M | 2.92× |
| 2025-06-30 | $361.12M | $129.16M | $132.47M | $168.71M | $59.94M | $49.83M | 2.80× |
| 2025-03-31 | $430.65M | $122.69M | $171.67M | $188.04M | $70.94M | $65.55M | 3.51× |
| 2024-12-31 | $393.12M | $122.34M | $115.69M | $208.09M | $69.34M | $51.52M | 3.21× |
| 2024-09-30 | $453.26M | $118.06M | $164.19M | $233.30M | $55.77M | $38.58M | 3.84× |
| 2024-06-30 | $444.15M | $93.64M | $228.68M | $183.86M | $31.60M | $27.85M | 4.74× |
| 2024-03-31 | $356.43M | $83.21M | $134.19M | $222.01M | $234.00K | $17.62M | 4.28× |
| 2023-12-31 | $280.02M | $110.31M | $114.89M | $164.98M | $151.00K | $10.37M | 2.54× |
| 2023-09-30 | (m) | $90.95M | $267.72M | $93.65M | (m) | $9.20M | (m) |
| 2023-06-30 | $250.93M | $88.64M | $230.01M | $20.88M | $33.00K | $9.72M | 2.83× |
| 2023-03-31 | (m) | $87.27M | $543.48M | $82.81M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $91.48M | $231.73M | $240.11M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $79.25M | $118.37M | $241.81M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $64.19M | $108.08M | $316.38M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $77.08M | $92.36M | $389.83M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $89.20M | $78.23M | $426.18M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $64.77M | $58.59M | $517.86M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $60.53M | $82.76M | $573.61M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $55.06M | $131.95M | $461.98M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $54.87M | $67.33M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $64.39M | $68.31M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $54.91M | $160.61M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $39.55M | $52.54M | $193.11M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $39.08M | $13.97M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $34.61M | $38.89M | $322.99M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $33.84M | $76.91M | $327.24M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $22.14M | $54.09M | $385.93M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $14.40M | $82.15M | $386.37M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $16.67M | $80.74M | $179.26M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $14.18M | $246.02M | $30.08M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $14.69M | $297.08M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $9.89M | $145.37M | $0.00 | (m) | (m) | (m) |
| 2017-09-30 | (m) | $8.53M | $163.38M | $0.00 | (m) | (m) | (m) |
| 2017-06-30 | (m) | $8.86M | $114.28M | $14.73M | (m) | (m) | (m) |
| 2017-03-31 | (m) | $5.50M | $107.10M | $40.10M | (m) | (m) | (m) |
| 2016-12-31 | (m) | $4.97M | $106.72M | $59.75M | (m) | (m) | (m) |
| 2016-09-30 | (m) | $3.19M | $92.89M | $86.39M | (m) | (m) | (m) |
| 2016-06-30 | (m) | $4.61M | $101.22M | $70.60M | (m) | (m) | (m) |
| 2016-03-31 | (m) | $1.83M | $8.94M | $60.25M | (m) | (m) | (m) |
| 2015-12-31 | (m) | $1.63M | $13.64M | $70.11M | (m) | (m) | (m) |
| 2015-09-30 | (m) | $2.85M | $10.21M | $79.37M | (m) | (m) | (m) |
| 2015-06-30 | (m) | $1.87M | $12.56M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $1.91M | $111.28M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $1.66M | $44.91M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $1.26M | $17.19M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $1.16M | $18.44M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $1.11M | $17.94M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $2.27M | $19.67M | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $3.51M | $129.80K | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $3.37M | $569.58K | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $12.31M | $0.00 | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $11.35M | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $16.61M | $0.00 | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $16.68M | $15.74K | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $17.34M | $0.00 | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $13.35M | $510.22K | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | $9.13M | $910.61K | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $1.87M | $268.56K | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $722.99K | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $822.87K | $1.29M | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $795.94K | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $209.26K | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $8.26K | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $2.90K | (m) | (m) | (m) | (m) |
| 2007-12-16 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2007-09-16 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |